Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Solbinsiran (LY3561774) in Adults With Severe Hypertriglyceridemia
jRCT2031250567Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in hypertriglyceridemia comparing Solbinsiran with Placebo (2 arms). Primary endpoint: Change from Baseline in Triglycerides. Started Jan 2026; status: active, not recruiting.
02
Drugs
solbinsiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on jRCT2031250567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250567.